P1/2, N=178, Recruiting, Shenzhen Ionova Life Sciences Co., Ltd. | Not yet recruiting --> Recruiting

P1, N=35, Not yet recruiting, Bayer Consumer Care AG

P1/2, N=120, Not yet recruiting, Verastem Inc.

However, DIO promoted recruitment of gMDSC and reductions in cytotoxic T cells within the 2838c3 T-cell inflamed TME, correlating with loss of control of microscopic disease. These findings suggest that DIO reduces the potency of targeted KRASG12D inhibition in T cell-inflamed PDAC.

P2, N=133, Recruiting, Zhejiang University | N=32 --> 133

P1, N=604, Recruiting, Revolution Medicines, Inc. | Trial primary completion date: Apr 2026 --> Dec 2026

P3, N=670, Recruiting, Revolution Medicines, Inc.

P1/2, N=178, Not yet recruiting, Shenzhen Ionova Life Sciences Co., Ltd.

P1/2, N=20, Active, not recruiting, West China Hospital | Trial primary completion date: Jan 2027 --> Aug 2026 | Recruiting --> Active, not recruiting

Several candidate ligands exhibited favorable binding affinity, stable proteinligand interactions, and enhanced structural stability compared with reference inhibitors, including MRTX1133 and BI-2852. Molecular dynamics analyses further supported the stability of the predicted complexes and the involvement of key binding residues within the KRAS G12D pocket. These findings demonstrate that MPFF-IS can efficiently identify potential KRAS G12D inhibitors and may provide a useful computational framework for precision drug discovery targeting difficult oncogenic proteins.

P1/2, N=84, Active, not recruiting, Revolution Medicines Inc. | Recruiting --> Active, not recruiting

Transmembrane oncoMUCs promote immune evasion in PDA through EGFR/UNC5B signaling, and their targeting enhances the efficacy of K-rasG12D inhibition, suggesting oncoMUCs as novel immune regulators and therapeutic targets in PDA.